The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testing.
Saved in:
| Title: | The MyCancerGene study: a hybrid type 1 effectiveness-implementation randomized study comparing a patient-centered digital genetic health portal to usual care after receipt of cancer genetic testing. |
|---|---|
| Authors: | Chavez-Yenter D; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA.; Department of Medical Ethics and Health Policy, The University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, USA., Fetzer D; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Egleston B; Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA., Domchek S; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Fleisher L; Fox Chase Cancer Center, Temple University, Philadelphia, PA, USA., Wagner LI; Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, NC, USA., Wen KY; Thomas Jefferson University, Philadelphia, PA, USA., Karpink K; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Gutstein L; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Posen S; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Selmani E; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., McLeod B; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Anantharajah A; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Brown S; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Cacioppo C; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Cappadocia J; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Ebrahimzadeh JE; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Falcone D; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Howe S; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Langer C; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., McCarthy-Wood B; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Weinberg M; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA., Bradbury AR; Abramson Cancer Center, Division of Hematology-Oncology, The University of Pennsylvania, Philadelphia, PA, USA. angela.bradbury@pennmedicine.upenn.edu.; Department of Medical Ethics and Health Policy, The University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, USA. angela.bradbury@pennmedicine.upenn.edu. |
| Source: | BMC cancer [BMC Cancer] 2025 Oct 24; Vol. 25 (1), pp. 1642. Date of Electronic Publication: 2025 Oct 24. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
